Identification
- Summary
Dexlansoprazole is a proton pump inhibitor used to treat erosive esophagitis, heartburn, and gastroesophageal reflux disease (GERD).
- Brand Names
- Dexilant
- Generic Name
- Dexlansoprazole
- DrugBank Accession Number
- DB05351
- Background
Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of Lansoprazole, which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation of PPIs (which includes Pantoprazole, Omeprazole, and Lansoprazole),6 dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing.1,3,6,9 Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme.10
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Dexlansoprazole (DB05351)
- Weight
- Average: 369.36
Monoisotopic: 369.075882366 - Chemical Formula
- C16H14F3N3O2S
- Synonyms
- (+)-2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE
- (R)-LANSOPRAZOLE
- 1H-BENZIMIDAZOLE, 2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-
- 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
- Dexlansoprazole
- LANSOPRAZOLE R-FORM
- LANSOPRAZOLE, (R)-
- External IDs
- NSC-758710
- T-168390
- TAK 390
- TAK-390
- TAK-390MR
- TAK390
Pharmacology
- Indication
Dexlansoprazole is a proton pump inhibitor (PPI) indicated for the:
- Healing of all grades of erosive esophagitis (EE) for up to eight weeks in patients 12 years of age and older.10
- Maintenance of healed EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age.10,11
- Treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks in patients 12 years of age and older.10,11
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Erosive esophagitis •••••••••••• •••••••• ••••••• ••••••• Management of Heartburn •••••••••••• ••••• •••••••• ••••••• •••••••• ••••••• •••••• ••••••••••••••• ••••••• ••••••• Management of Heartburn •••••••••••• •••••••••• •••••••• ••••••• •••••••• ••••••• •••••• ••••••••••••••• ••••••• ••••••• Management of Healed erosive esophagitis •••••••••••• ••••• •••••••• ••••••• •••••••• ••••••• •••••• ••••••••••••••• ••••••• ••••••• Management of Healed erosive esophagitis •••••••••••• •••••••••• •••••••• ••••••• •••••••• ••••••• •••••• ••••••••••••••• ••••••• ••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Dexlansoprazole is a proton pump inhibitor (PPI) that suppresses both basal and stimulated gastric acid secretion.10 PPIs are associated with a risk for a rebound effect and a short-term increase in hypersecretion; thus, such risk cannot be excluded with dexlansoprazole.8 With long-term use, PPIs are also associated with a risk of increased susceptibility to bacterial infections, vitamin B12 and iron deficiency, and hypomagnesemia and hypocalcemia, possibly leading to osteoporosis and bone fractures.7
Dexlansoprazole is reported to interfere with the secretin stimulation test and create false positive urine screening tests for tetrahydrocannabinol. Dexlansoprazole can increase gastrin levels, which can cause enterochromaffin-like cell hyperplasia and increase serum CgA levels. Increased CgA levels may cause false positive results in diagnostic investigations for neuroendocrine tumours.10
- Mechanism of action
Dexlansoprazole suppresses gastric acid secretion by blocking the final step of acid production. It inhibits the H/K ATPase at the secretory surface of the gastric parietal cell, which is involved in the secretion of hydrochloric acid.10 H/K ATPase is a proton pump responsible for hydrolyzing ATP and exchanging H+ ions from the cytoplasm for K+ ions in the secretory canaliculus: this action results in hydrochloric acid secretion into the gastric lumen.2
Target Actions Organism APotassium-transporting ATPase alpha chain 1 inhibitorHumans APotassium-transporting ATPase subunit beta inhibitorHumans UN(G),N(G)-dimethylarginine dimethylaminohydrolase 1 Not Available Humans - Absorption
The dual delayed-release formulation of dexlansoprazole results in a plasma concentration-time profile with two distinct peaks; the first peak occurs one to two hours after administration, followed by a second peak within four to five hours. About 25% of the dose is released at the pH level of 5.5 in the proximal duodenum, while the other 75% is released in the distal small intestine at the pH level of 6.75.2,10
After oral administration of dexlansoprazole 30 or 60 mg to healthy subjects and symptomatic GERD patients, mean Cmax and AUC values of dexlansoprazole increased approximately dose-proportionally. Following administration of 30 mg in healthy adults, the mean (%CV) Cmax and AUC were 658 (40%) ng/mL and 3275 (47%) ng x h/mL, respectively. At a dose of 60 mg, the mean (%CV) Cmax and AUC were 1397 (51%) ng/mL and 6529 (60%) ng x h/mL, respectively. In healthy subjects, food increased Cmax by 12 to 55% and AUC by 9 to 37%. The effect of food on Tmax varied, as both an increase and a decrease was observed.10
- Volume of distribution
The apparent volume of distribution (Vz/F) after multiple doses in symptomatic GERD patients was 40 L.10
- Protein binding
Plasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.10
- Metabolism
Dexlansoprazole is extensively metabolized in the liver. It undergoes oxidation and reduction, followed by subsequent sulfation, glucuronidation, and glutathione conjugation to form inactive metabolites. Oxidative metabolites are formed from CYP2C19-mediated hydroxylation and CYP3A4-mediated oxidation to the sulfone.5,10
CYP2C19 is a polymorphic liver enzyme which exhibits three phenotypes in the metabolism of CYP2C19 substrates: extensive metabolizers (1/1), intermediate metabolizers (*1/mutant) and poor metabolizers (mutant/mutant). Dexlansoprazole is the major circulating component in plasma regardless of CYP2C19 metabolizer status. In CYP2C19 intermediate and extensive metabolizers, the major plasma metabolites are 5-hydroxy dexlansoprazole and its glucuronide conjugate, while in CYP2C19 poor metabolizers dexlansoprazole sulfone is the major plasma metabolite.10
Hover over products below to view reaction partners
- Route of elimination
Dexlansoprazole does not appear to be eliminated unchanged in the urine.4,10 Following the administration of [14C] dexlansoprazole to six healthy male subjects, approximately 50.7% (standard deviation (SD): 9.0%) of the administered radioactivity was excreted in urine and 47.6% (SD: 7.3%) in the feces.10
- Half-life
Dexlansoprazole is eliminated with a half-life of approximately one to two hours.4,10
- Clearance
Apparent clearance (CL/F) in healthy subjects was 11.4 to 11.6 L/hour, respectively, after five days of 30 or 60 mg once daily administration.10
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Oral LD50 value in mice, rats and dogs is reported to be > 5000 mg/kg.12
There have been no reports of significant overdose with dexlansoprazole. Multiple doses of 120 mg and a single dose of 300 mg did not result in death or other severe adverse events; however, serious adverse events of hypertension have been reported in association with twice daily doses of 60 mg. Nonserious adverse reactions observed with twice daily doses of 60 mg include hot flashes, contusion, oropharyngeal pain, and weight loss. Dexlansoprazole is not expected to be removed from the circulation by hemodialysis. In the event of over-exposure, treatment should be symptomatic and supportive.10
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details Cytochrome P450 2C19 CYP2C19*2A Not Available 681G>A Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2C19 CYP2C19*2B Not Available 681G>A Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2C19 CYP2C19*3 Not Available 636G>A Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2C19 CYP2C19*4 Not Available 1A>G Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2C19 CYP2C19*5 Not Available 1297C>T Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2C19 CYP2C19*6 Not Available 395G>A Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2C19 CYP2C19*7 Not Available 19294T>A Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2C19 CYP2C19*22 Not Available 557G>C / 991A>G Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2C19 CYP2C19*24 Not Available 99C>T / 991A>G … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2C19 CYP2C19*35 Not Available 12662A>G Effect Inferred Poor drug metabolizer. Details
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of Dexlansoprazole can be increased when it is combined with Abametapir. Abatacept The metabolism of Dexlansoprazole can be increased when combined with Abatacept. Abrocitinib The metabolism of Abrocitinib can be decreased when combined with Dexlansoprazole. Acenocoumarol The risk or severity of bleeding can be increased when Dexlansoprazole is combined with Acenocoumarol. Adalimumab The metabolism of Dexlansoprazole can be increased when combined with Adalimumab. - Food Interactions
- Avoid St. John's Wort. It may induce the CYP3A4 metabolism of dexlansoprazole, possibly leading to reduced efficacy.
- Take with or without food. Dexlansoprazole's dual delayed release formulation allows it to be taken without regard to food in contrast to other PPIs.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Dexlansoprazole sesquihydrate HS2S9VK3NH 313640-86-7 XTQWZVSRVXCIGB-BBBDYAHLSA-N - Product Images
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Dexilant Capsule, delayed release 60 mg Nasogastric; Oral Takeda 2010-08-05 Not applicable Canada 
Dexilant Capsule, delayed release 60 mg/1 Oral Cardinal Health 107, LLC 2010-04-12 2025-04-30 US 
Dexilant Capsule, delayed release 30 mg/1 Oral Takeda Pharmaceuticals America, Inc. 2010-04-12 Not applicable US 
Dexilant Capsule, delayed release 60 mg/1 Oral Physicians Total Care, Inc. 2010-08-19 Not applicable US 
Dexilant Capsule, delayed release 60 mg/1 Oral A-S Medication Solutions 2010-04-12 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Dexlansoprazole Capsule, delayed release 60 mg/1 Oral bryant ranch prepack 2022-11-22 Not applicable US Dexlansoprazole Capsule, delayed release 30 mg/1 Oral Par Pharmaceutical, Inc. 2023-06-10 Not applicable US Dexlansoprazole Capsule, delayed release 30 mg/1 Oral bryant ranch prepack 2023-06-10 Not applicable US Dexlansoprazole Capsule, delayed release 60 mg/1 Oral Par Pharmaceutical, Inc. 2022-11-22 Not applicable US Dexlansoprazole Capsule, delayed release pellets 60 mg/1 Oral Mylan Pharmaceuticals Inc. 2024-01-22 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image DEXGARD 30/30 MG MR KAPSUL, 30 ADET Dexlansoprazole (30 mg) + Domperidone (30 mg) Capsule Oral NUVOMED İLAÇ SAN.TİC. A.Ş. 2012-07-31 Not applicable Turkey 
DEXGARD 30/30 MG MR KAPSUL, 60 ADET Dexlansoprazole (30 mg) + Domperidone (30 mg) Capsule Oral NUVOMED İLAÇ SAN.TİC. A.Ş. 2012-07-31 Not applicable Turkey DUEDOM 30/10 MG KAPSÜL, 30 ADET Dexlansoprazole (30 mg) + Domperidone (10 mg) Capsule Oral CELTİS İLAÇ SAN. VE TİC. A.Ş. 2011-12-22 Not applicable Turkey DUEDOM 60/10 MG KAPSÜL, 30 ADET Dexlansoprazole (60 mg) + Domperidone (10 mg) Capsule Oral CELTİS İLAÇ SAN. VE TİC. A.Ş. 2011-12-22 Not applicable Turkey
Categories
- ATC Codes
- A02BC06 — Dexlansoprazole
- Drug Categories
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Acid Reducers
- Alimentary Tract and Metabolism
- Anti-Ulcer Agents
- Benzimidazoles
- Cytochrome P-450 CYP2C19 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors (weak)
- Cytochrome P-450 CYP2C19 Substrates
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Substrates
- Drugs for Acid Related Disorders
- Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
- Enzyme Inhibitors
- Gastric Acid Lowering Agents
- Gastrointestinal Agents
- Heterocyclic Compounds, Fused-Ring
- Proton Pump Inhibitors
- Proton-pump Inhibitors
- Pyridines
- Sulfoxides
- Sulfur Compounds
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzimidazoles
- Sub Class
- Sulfinylbenzimidazoles
- Direct Parent
- Sulfinylbenzimidazoles
- Alternative Parents
- Methylpyridines / Alkyl aryl ethers / Benzenoids / Imidazoles / Heteroaromatic compounds / Sulfoxides / Sulfinyl compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds show 4 more
- Substituents
- Alkyl aryl ether / Alkyl fluoride / Alkyl halide / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Ether / Heteroaromatic compound / Hydrocarbon derivative show 15 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- UYE4T5I70X
- CAS number
- 138530-94-6
- InChI Key
- MJIHNNLFOKEZEW-RUZDIDTESA-N
- InChI
- InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
- IUPAC Name
- 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl]-1H-1,3-benzodiazole
- SMILES
- CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1
References
- General References
- Behm BW, Peura DA: Dexlansoprazole MR for the management of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):439-45. doi: 10.1586/egh.11.37. [Article]
- Skrzydlo-Radomanska B, Radwan P: Dexlansoprazole - a new-generation proton pump inhibitor. Prz Gastroenterol. 2015;10(4):191-6. doi: 10.5114/pg.2015.56109. Epub 2015 Dec 16. [Article]
- Frye JW, Peura DA: Managing gastroesophageal reflux disease - comparative efficacy and outcomes of dexlansoprazole MR. Ther Clin Risk Manag. 2015 Oct 30;11:1649-56. doi: 10.2147/TCRM.S66680. eCollection 2015. [Article]
- Wittbrodt ET, Baum C, Peura DA: Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis. Clin Exp Gastroenterol. 2009;2:117-28. Epub 2009 Nov 17. [Article]
- Grabowski B, Lee RD: Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects. Clin Drug Investig. 2012 May 1;32(5):319-32. doi: 10.2165/11630930-000000000-00000. [Article]
- Tytgat GN: Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol. 2001 May;13 Suppl 1:S29-33. [Article]
- Haastrup PF, Thompson W, Sondergaard J, Jarbol DE: Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol. 2018 Aug;123(2):114-121. doi: 10.1111/bcpt.13023. Epub 2018 May 24. [Article]
- Reimer C, Sondergaard B, Hilsted L, Bytzer P: Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009 Jul;137(1):80-7, 87.e1. doi: 10.1053/j.gastro.2009.03.058. Epub 2009 Apr 10. [Article]
- Shin JM, Kim N: Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013 Jan;19(1):25-35. doi: 10.5056/jnm.2013.19.1.25. Epub 2013 Jan 8. [Article]
- DailyMed Label: DEXILANT (dexlansoprazole) delayed-release capsules, for oral use [Link]
- FDA Approved Drug Products: DEXILANT (dexlansoprazole) Oral Delayed-release capsules or DEXILANT SOLUTAB (dexlansoprazole) delayed-release orally disintegrating tablets (October 2016) [Link]
- TWi Pharmaceuticals: Dexlansoprazole MSDS [Link]
- External Links
- PubChem Compound
- 9578005
- PubChem Substance
- 347827723
- ChemSpider
- 7852369
- BindingDB
- 50247930
- 816346
- ChEBI
- 135931
- ChEMBL
- CHEMBL1201863
- ZINC
- ZINC000003830986
- PharmGKB
- PA166110257
- Wikipedia
- Dexlansoprazole
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Barrett's Esophagus / Inflammation 1 4 Completed Treatment Gastro-esophageal Reflux Disease (GERD) 2 4 Completed Treatment Gastro-esophageal Reflux Disease (GERD) / Proton Pump Inhibitors 1 4 Completed Treatment H Pylori Infection Eradication 1 4 Completed Treatment Helicobacter Pylori Infection 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet 30 mg Tablet 60 mg Capsule Oral Capsule Oral 60.00 mg Capsule, delayed release Nasogastric; Oral 30 mg Capsule, delayed release Nasogastric; Oral 60 mg Capsule, delayed release Oral 60 mg/1 Capsule Oral 30 mg Capsule Oral 60 mg Capsule, delayed release 60 mg Capsule, extended release Oral 30 MG Capsule, extended release Oral 60 MG Capsule, delayed release Oral 30 mg Capsule, delayed release Oral 60 mg Capsule, delayed release Oral Tablet, orally disintegrating, delayed release Oral 30 mg/1 Capsule, delayed release 30 mg Capsule Oral 7.500 mg Capsule, delayed release pellets Oral 30 mg/1 Capsule, delayed release pellets Oral 60 mg/1 Capsule, coated Oral 30 mg Capsule, coated Oral 3000000 mg Capsule, coated Oral 6000000 mg Capsule, delayed release Oral 6000000 mg Capsule, delayed release Oral 30 mg/1 Capsule, coated Oral 60 mg - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region CA1327010 No 1994-02-15 2011-02-15 Canada CA2375201 No 2010-02-09 2020-06-15 Canada US7399485 Yes 2008-07-15 2018-11-26 US US6328994 Yes 2001-12-11 2019-11-17 US US7875292 Yes 2011-01-25 2019-11-17 US US7431942 Yes 2008-10-07 2019-11-17 US US6462058 Yes 2002-10-08 2020-12-15 US US6939971 Yes 2005-09-06 2020-12-15 US US8173158 Yes 2012-05-08 2030-09-17 US US6664276 Yes 2003-12-16 2023-07-30 US US8784885 Yes 2014-07-22 2024-04-15 US US9233103 No 2016-01-12 2032-03-05 US US9011926 No 2015-04-21 2026-02-24 US US9238029 No 2016-01-19 2026-01-17 US US8722084 Yes 2014-05-13 2024-04-15 US US9145389 No 2015-09-29 2020-06-15 US US8871273 Yes 2014-10-28 2028-07-11 US US8461187 Yes 2013-06-11 2026-07-17 US US8105626 Yes 2012-01-31 2027-03-27 US US7285668 Yes 2007-10-23 2020-12-15 US US7790755 Yes 2010-09-07 2027-02-02 US US9241910 No 2016-01-26 2029-03-10 US US6238994 Yes 2001-05-29 2019-11-17 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.25 mg/mL ALOGPS logP 2.84 ALOGPS logP 3.03 Chemaxon logS -3.2 ALOGPS pKa (Strongest Acidic) 9.35 Chemaxon pKa (Strongest Basic) 4.16 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 67.87 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 87.61 m3·mol-1 Chemaxon Polarizability 34.5 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0fk9-0059000000-f06d77d09a86f5e2bf71 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0v59-0769000000-b68e645e752cc42ba812 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-0900000000-2b57a28f448d017c174c Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-014l-1933000000-25b5d7be37adf65fa45f Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0uyr-0930000000-bb49b5d18d287fcc5ad3 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-0910000000-674886b87ab10a6d4082 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 175.42035 predictedDeepCCS 1.0 (2019) [M+H]+ 177.77835 predictedDeepCCS 1.0 (2019) [M+Na]+ 184.21729 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Sodium:potassium-exchanging atpase activity
- Specific Function
- Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
- Gene Name
- ATP4A
- Uniprot ID
- P20648
- Uniprot Name
- Potassium-transporting ATPase alpha chain 1
- Molecular Weight
- 114117.74 Da
References
- Shin JM, Kim N: Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013 Jan;19(1):25-35. doi: 10.5056/jnm.2013.19.1.25. Epub 2013 Jan 8. [Article]
- FDA Approved Drug Products: DEXILANT (dexlansoprazole) Oral Delayed-release capsules or DEXILANT SOLUTAB (dexlansoprazole) delayed-release orally disintegrating tablets (October 2016) [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Hydrogen:potassium-exchanging atpase activity
- Specific Function
- Required for stabilization and maturation of the catalytic proton pump alpha subunit and may also involved in cell adhesion and establishing epithelial cell polarity.
- Gene Name
- ATP4B
- Uniprot ID
- P51164
- Uniprot Name
- Potassium-transporting ATPase subunit beta
- Molecular Weight
- 33366.95 Da
References
- Shin JM, Kim N: Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013 Jan;19(1):25-35. doi: 10.5056/jnm.2013.19.1.25. Epub 2013 Jan 8. [Article]
- FDA Approved Drug Products: DEXILANT (dexlansoprazole) Oral Delayed-release capsules or DEXILANT SOLUTAB (dexlansoprazole) delayed-release orally disintegrating tablets (October 2016) [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Metal ion binding
- Specific Function
- Hydrolyzes N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation.
- Gene Name
- DDAH1
- Uniprot ID
- O94760
- Uniprot Name
- N(G),N(G)-dimethylarginine dimethylaminohydrolase 1
- Molecular Weight
- 31121.5 Da
References
- Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, Leiper J, Cooke JP: Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013 Aug 20;128(8):845-53. doi: 10.1161/CIRCULATIONAHA.113.003602. Epub 2013 Jul 3. [Article]
- Tommasi S, Elliot DJ, Hulin JA, Lewis BC, McEvoy M, Mangoni AA: Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance. Sci Rep. 2017 Jun 6;7(1):2871. doi: 10.1038/s41598-017-03069-1. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- Curator comments
- AAlthough in vitro studies indicated that dexlansoprazole has the potential to inhibit CYP2C19 in vivo, an in vivo drug- drug interaction study in mainly CYP2C19 extensive and intermediate metabolizers has shown that dexlansoprazole does not affect the pharmacokinetics of CYP2C19 substrates.
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Goh KL, Choi MG, Hsu PI, Chun HJ, Mahachai V, Kachintorn U, Leelakusolvong S, Kim N, Rani AA, Wong BC, Wu J, Chiu CT, Shetty V, Bocobo JC, Chan MM, Lin JT: Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region. J Neurogastroenterol Motil. 2016 Jul 30;22(3):355-66. doi: 10.5056/jnm15150. [Article]
- Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [Article]
- FDA Approved Drug Products: DEXILANT (dexlansoprazole) Oral Delayed-release capsules or DEXILANT SOLUTAB (dexlansoprazole) delayed-release orally disintegrating tablets (October 2016) [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- FDA Approved Drug Products: DEXILANT (dexlansoprazole) Oral Delayed-release capsules or DEXILANT SOLUTAB (dexlansoprazole) delayed-release orally disintegrating tablets (October 2016) [Link]
Drug created at November 18, 2007 18:24 / Updated at February 20, 2024 23:55